Tilray Brands, Inc.

TLRY Healthcare Drug Manufacturers Specialty & Generic

Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.04 0.17 −5.30%
Market cap
$474.4M
P/E
0.0×
Fwd P/E
−14.8×
Dividend yield
—
F-score
3/9
Altman Z
−1.96
Beneish M
−2.01
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Older periods Nov '25 Feb '26 May '26 Aug '26
Net Income

+8 more TTM periods

(2,103.42) (1,335.12) (105.16) (146.70)
Operating Cash Flow
(28.45) (44.63) (69.14) (84.34)
Investing cash flow
(20.14) 8.90 (55.80) (89.52)
Financing cash flow
102.66 79.46 130.99 125.11
Ending Cash
278.67 271.22 229.34 182.86

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 13 Oct 2026